Newly-released Aquaculture Vaccines Market industry analysis report by Future Market Insights shows that global sales of the Aquaculture Vaccines Market in 2022 were held at USD 374.9 Million. With 8.5%, the projected market growth from 2023 to 2033 is expected to be higher than the historical growth. The Injected Vaccines are expected to be the significant revenue-generating segment, expected to account for a CAGR of 8.6% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Aquaculture Vaccines Market (2023) | USD 406 Million |
| Global Aquaculture Vaccines Market (2033) | USD 913.6 Million |
| Global Aquaculture Vaccines Market CAGR (2023 to 2033) | 8.5% |
| USA Aquaculture Vaccines Market CAGR (2023 to 2033) | 8.1% |
| Key Companies Profiled | GlaxoSmithKline plc; Merck & Co., Inc; Pfizer, Inc.; Sanofi SA; CSL Limited; Emergent BioSolutions, Inc.; Johnson & Johnson; AstraZeneca plc; Serum Institute of India Pvt. Ltd.; Bavarian Nordic A/S; Mitsubishi Tanabe Pharma Corporation; Daiichi Sankyo Company, Limited; Panacea Biotec, Ltd.; Biological E Limited; Bharat Biotech Ltd.; Novavax, Inc.; FSUE NPO Microgen; Sinovac Biotech, Ltd.; Incepta Vaccine Limited; Valneva SE; VBI Vaccines; PT Bio Farma; Inovio Pharmaceuticals, Inc.; Chongqing Zhifei Biological Products Co.Ltd.; Indian Immunologicals Limited |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Aquaculture Vaccines Market industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value of the Aquaculture Vaccines Market industry increased at around 8.1% CAGR, wherein, countries such as the USA, UK, China, Japan, and South Korea held a significant share in the global market.
Vaccines are used to prevent a number of diseases in companion animals, as well as terrestrial cattle. In the aquaculture industry, diseases occur more frequently and replicate fast. The most significant variables to expand aquatic animal healthcare are general management and suitable husbandry, which include immunity, genetics, system management, nutrition, and water quality.
The ideal vaccination should be safe for the fish, the people vaccinating the fish, and the end-user, while also protecting against numerous diseases and assisting in the prevention of any sickness. It also provides long-term protection throughout the life cycle. Vaccines for aquaculture are produced in such a way that they are simple to use and may be used on a variety of fish species at the same time. One of the prime requirements of these vaccines is that they should be affordable, and must be licensed and registered with the FDA.
Vaccination of farmed fish provides considerable benefits in the fight against viral and bacterial infections while avoiding the negative side effects of medications. Antibiotic usage also leads to antibiotic resistance, which leads to a loss of aquaculture output and severe economic losses.
Antibiotics are no longer used in aquaculture operations in certain European nations, such as Norway. This has had a good impact on the market for aquaculture vaccinations, as well as minimizing the risk of antibiotic resistance. Furthermore, due to technological developments, the adoption of aquaculture vaccinations would grow as opposed to antibiotics, with the advent of DNA and subunit vaccines.
Principal Consultant
The aquaculture vaccines market in North America is expected to grow at a CAGR of 8%. Key businesses like Zoetis Inc. and Merck & Co. are increasing their research and development investments, which is boosting regional industry revenue. Furthermore, government financing for the development of aquaculture vaccines will boost market share.
Throughout the projected period, Europe will continue to be one of the most lucrative markets for commercial aquaculture vaccinations. For instance, Norway is one of the prominent salmon exporters globally, owing to its supportive government and private-sector activities, increased human concerns about antibiotic resistance, and the presence of key players.
The Norwegian Medicines Agency has particular regulations and standards for autogenous vaccination applications. Furthermore, autogenous vaccinations should only be utilized in the event that commercial vaccines are unavailable or do not provide sufficient protection. Under the 7th Framework Program, the European Commission supported a large-scale collaborative project to support the aquaculture industry.
Asia-Pacific is another lucrative market for aquaculture where several aquatic species, such as tilapia, are produced in abundance. Due to factors such as rising demand for marine foods, a developing aquaculture industry, the availability of sufficient water resources across key countries, supportive government initiatives, and the growing practice of sustainable aquaculture, the market in the Asia Pacific is expected to grow significantly throughout the forecast period.
The market for aquaculture vaccines in the USA is expected to reach a market size of USD309 Million by 2033. The market in the country is expected to swell at a CAGR of 8.1% from 2023 to 2033, with an absolute dollar opportunity of USD 167 Million.
The market in the UK is expected to reach a valuation of USD 41 Million by 2033. Growing with a CAGR of 9.8% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of USD 13.7 Million.
In Japan, the market is expected to grow at a CAGR of 8% from 2023 to 2033, reaching USD 29 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of USD 15.6 Million during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In 2020, the inactivated vaccines held a significant market share of over 30%. Inactivated bacterial and viral vaccines are produced in huge numbers by fermenting disease-causing microorganisms. After that, inactivating chemicals like formalin are used to destroy all of the bacteria. Because they retain their basic shape, antigen properties, and structure, these inactivated organisms provoke an immunological response.
In 2020, the injected vaccines held a prominent market share of over 35%. Elanco's Apex-IHN is the first DNA vaccine to be approved in Canada for IHNV protection in healthy salmonid fish. Injectable Aquaculture Vaccines for protection against diseases such as vibriosis, furunculosis, winter sore, cold-water vibriosis, Infectious Salmon Anemia, and IPN, are a part of Zoetis' Alpha Ject portfolio.
During the projection period, revenue through oral vaccines is projected to grow at a CAGR of 8.7%. Oral immunization has several advantages over alternative delivery methods. The procedure is non-invasive, does not need handling of the fish, is simple to administer and can be used to immunize large groups of people. This contributes to the segment's expansion.
In 2020, the aquaculture vaccines market accounted for a share of over 43% through bacterial application. The USDA's Aquatic Animal Health Research has identified bacterial species from more than 20 genera as the causal agents of Aquatic illnesses. They have an impact on over 20 kinds of freshwater and marine fish. Aquatic infections cause enormous economic losses in the aquaculture business, with yearly losses estimated to be in the hundreds of millions of dollars.
During the projected period, the revenue through the viral application of aquaculture vaccines is expected to grow at a CAGR of around 9%. According to a report by the Responsible Use of Medicines in Agriculture Alliance (RUMA), the primary types of fish grown via aquaculture that are routinely vaccinated, are Atlantic salmon, rainbow trout, and Atlantic cod.
Companies in the commercial aquaculture vaccines industry are focusing on strategic acquisitions of new innovative firms and value chain alliances. Leading vaccine makers are working on the difficulties faced by aquaculture farmers and responding to their needs for sustainable fish aquaculture farming by releasing effective and easy-to-use commercial aquaculture vaccines. These initiatives are intended to help them increase their sales in the commercial aquaculture vaccines market around the world.
Some of the recent developments of key players in the Aquaculture Vaccines Market are as follows:
This collaboration is expected to provide Africa, Asia, and Latin America with a complete and novel spectrum of tilapia vaccinations. This strategy allowed the corporation to add value to its existing portfolio while also expanding its customer base into previously unexplored markets.
Similarly, recent developments related to companies offering Aquaculture Vaccines Market have been tracked by the team at Future Market Insights, which are available in the full report.
The global aquaculture vaccines market is valued at USD 406 million in 2023.
There are various vaccines used in aquaculture such as attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines.
Asia Pacific is leading the aquaculture vaccines market.
The top five countries are Norway, Chile, Vietnam, China, and the United States.
Key trends shaping the market include rising demand for sustainable seafood and increased focus on disease prevention.
1. Executive Summary 2. Market Overview 3. Market Risks and Trends Assessment 4. Market Background 5. Key Success Factors 6. Global Market Demand Analysis 2018 to 2022 and Forecast, 2023 to 2033 7. Global Market Value Analysis 2018 to 2022 and Forecast, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 8.1. Attenuated Live Vaccines 8.2. Inactivated Vaccines 8.3. Subunit Vaccines 8.4. DNA Vaccines 8.5. Recombinant Vaccines 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 9.1. Oral 9.2. Injected 9.3. Immersion & Spray 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 10.1. Bacterial 10.2. Viral 10.3. Parasitic 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. Asia Pacific 11.5. Middle East and Africa (MEA) 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17. Key Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18. Market Structure Analysis 19. Competition Analysis 19.1. IBM 19.2. SYMANTEC 19.3. MICRO FOCUS 19.4. QUALYS 19.5. SOLARWINDS 19.6. IVANTI 19.7. MANAGEENGINE 19.8. CONNECTWISE 19.9. AVAST 19.10. AUTOMOX 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Aquaculture Vaccines Market
